Literature DB >> 12960926

Acute portal hemodynamics and cytokine changesfollowing selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma.

Laurent Spahr1, Christoph Becker, Jérôme Pugin, Pietro E Majno, Antonine Hadengue.   

Abstract

BACKGROUND: Altered portal hemodynamics and inflammation may occur following transcatheter arterial chemoembolization (TACE), but early biological and portal perfusion changes are not well characterized when this procedure is performed selectively. MATERIAL/
METHODS: We studied variations in portal flow velocity (PFV) using Doppler ultrasonography, as well as serum TNFa, vCAM-1, and E-Selectin at 2 and 24 hours after supraselective TACE in 15 consecutive patients with cirrhosis and hepatocellular carcinoma.
RESULTS: Variations in PFV occurred both in the embolized and non-embolized liver lobe. PFV increased significantly at 2 hours in the right and left portal vein. At 24 hours, right PFV remained elevated. Serum TNFa increased significantly at 2 hours, but VCAM-1 and E-Selectin levels remained unchanged. Changes in right and left PFV showed a positive correlation (r=0.9, p<0.001). No correlation could be observed between biological and Doppler changes in portal veins.
CONCLUSIONS: In patients with cirrhosis and hepatocellular carcinoma, PFV increased in both liver lobes 2 hours after supraselective TACE, in association with high serum TNFa. Diffuse changes in PFV after TACE suggests that mechanisms involved in the regulation of portal and hepatic arterial hemodynamics are present in patients with cirrhosis. A major role for TNFa in acute portal flow velocity variations is unlikely in this situation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960926

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

1.  Complications of hepatic chemoembolization.

Authors:  Timothy W I Clark
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

2.  Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma.

Authors:  Moana Gelu-Simeon; Didier Samuel
Journal:  Hepatol Int       Date:  2013-09-10       Impact factor: 6.047

3.  Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.

Authors:  Yee Chao; Chen-Yi Wu; Chen-Yu Kuo; Jack P Wang; Jiing-Chyuan Luo; Chien-Hui Kao; Rheun-Chuan Lee; Wei-Ping Lee; Chung-Pin Li
Journal:  Hepatol Int       Date:  2012-11-21       Impact factor: 6.047

Review 4.  Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law.

Authors:  Gerond Lake-Bakaar; Muneeb Ahmed; Amy Evenson; Alan Bonder; Salomao Faintuch; Vinay Sundaram
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

5.  Correlation of baseline Portal pressure (hepatic venous pressure gradient) and Indocyanine Green Clearance Test With Post-transarterial Chemoembolization Acute Hepatic Failure.

Authors:  Rohit Khisti; Yashwant Patidar; Lalit Garg; Amar Mukund; Sherin Sarah Thomas; Shiv K Sarin
Journal:  J Clin Exp Hepatol       Date:  2018-10-09

6.  Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).

Authors:  Philipp Wiggermann; Dominik Sieron; Christiane Brosche; Thomas Brauer; Fabian Scheer; Ivan Platzek; Wojciech Wawrzynek; Christian Stroszczynski
Journal:  Med Sci Monit       Date:  2011-04

7.  Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure.

Authors:  Constantine Frangakis; Jae Ho Sohn; Ahmet Bas; Julius Chapiro; Ruediger E Schernthaner; MingDe Lin; James P Hamilton; Timothy M Pawlik; Kelvin Hong; Rafael Duran
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.